Ventricular tachycardia in repaired congenital heart disease by Katja Zeppenfeld
Schwerpunkt
Herzschr Elektrophys 2016 · 27:131–136
DOI 10.1007/s00399-016-0428-4
Received: 29 February 2016
Accepted: 26 March 2016
Published online: 19 May 2016
© The Author(s) 2016 . This article is available
at SpringerLink with Open Access
Katja Zeppenfeld
Department of Cardiology, C5-P, Leiden University Medical Centre, Leiden, The Netherlands
Ventricular tachycardia in
repaired congenital heart disease
The population of adults with repaired
congenital heart disease (rCHD) is grow-
ing [21]. Surgical approaches and the
timing of intervention have changed over
the past few decades with better survival
in infancy and a trend toward death at
older age [15]. Improved survival ex-
posesmorepatients to the riskof late ven-
tricular arrhythmias (VA) contributing
to morbidity and sudden cardiac death
(SCD). Knowledge of the individualmal-
formation, the type of repair, and the
related VA is a prerequisite for risk strat-
iﬁcation and therapeutic interventions.
Type andmechanism of VA
Although suddendeathmayoccasionally
be due to cerebral, vascular, or thrombo-
embolic events, the majority is assumed
to be arrhythmic SCD [19]. Life-threat-
ening arrhythmias rarely occur during
childhood, and a time-dependent incre-
mental risk for VA and SCD has been
observed particularly in patients with re-
paired tetralogy of Fallot (rTOF) [6].
Although systemic ventricular dys-
function is a dominant predictor for SCD
in unselected populations of adults with
CHD, two thirds of those who die sud-
denly or experience life-threatening VTs
have a preserved cardiac function prior
to the event [4, 5, 19, 24]. These data
suggest that diﬀerent VA mechanisms
may be operative.
VAs include monomorphic ventricu-
lar tachycardia (MVT), polymorphic VT,
and ventricular ﬁbrillation. It is crucial
for risk stratiﬁcation and treatment to
understand and identify the underlying
substrate for these diﬀerentVAs. VAs can
occur in the absence of any surgical scar
orpatchmaterial, typical forpatientswith
left heart obstruction or atrial switch op-
eration for simple dextro-transposition
of the great arteries (d-TGA).
However,MVTin thesepatients isun-
common. The estimated incidence rate
for MVT in an unselected group of pa-
tients after atrial switch for d-TGA was
0.5%peryear [24]. Themajorityofdocu-
mentedVAs in d-TGApatients who have
received an implantable cardioverter de-
ﬁbrillator (ICD) were polymorphic VT
or ventricular ﬁbrillation [13].
The underlying arrhythmia mecha-
nisms are likely to be similar to those
observed in other cardiac diseases with
pathologic hypertrophy, ﬁbrosis, pro-
gressive right or left ventricular di-
latation, and eventually heart failure.
Hypertrophy can be due to chronic pres-
sure overload in left heart obstructions.
Progressive ventricular dysfunction usu-
ally occurs if the right ventricle (RV)
serves as the systemic ventricle after
atrial switch operation for d-TGA or in
congenitally corrected transposition of
the great arteries (ccTGA). The ther-
apeutic options comprise treatment of
residual lesions, optimal heart failure
management to reduce further adverse
remodeling, and ICD implantation. Spe-
ciﬁc anti-arrhythmic drugs or catheter or
surgical interventions are not available.
By contrast, in the presence of sur-
gical scar and patch material, MVTs are
the most common type of observed VAs.
MVT after repair of TOF can serve as
a paradigm of these postoperative ar-
rhythmias [11, 20, 26].
Indeed, more than 80% of all treated
VAs in rTOF patients who have received
ICDs for primary and secondary preven-
tion were monomorphic and fast VTs
with a median heart rate of 212 bpm
[14]. These fast VTs can be fatal, even in
the presence of a preserved cardiac func-
tion. MVTs have also been described
after ventricular septal defect (VSD) clo-
sure and repair of complex d-TGA. The
latter is associated with VSD in approx-
imately 40% of cases, or less frequently
with pulmonary outﬂow tract obstruc-
tion, andmay provide a similar substrate
for macro-reentrant VTs than those ob-
served in rTOF.
After initial repair of TOF, RV hyper-
trophy may develop as a result of resid-
ual RVOT obstructions. Progressive RV
dilatation and dysfunction can be the
consequence of chronic pulmonary re-
gurgitation, which is more likely if ini-
tial repair is performed through a right
ventriculotomy combined with the use
of large transannular patches (. Fig. 1).





Areas of dense ﬁbrosis after surgical in-
cisions, patch material, and the valve an-
nuli form regions of conduction block
that can deﬁne reentry circuit borders
and create intervening anatomical isth-
muses(AIs)consistingofconductingmy-
ocardium [11, 26]. After repair of TOF,
four AIs related to VT have been de-
scribed, whose presence is dependent on
the variationof themalformation and the
type of repair (. Fig. 2; [26]). Isthmus 1 is
borderedbythe tricuspidannulusandthe
transversal or longitudinal surgical RV
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Fig. 18 Cardiacmagnetic resonance imaging (MRI;a) and intraoperativeﬁndings (b) of apatientwith
repaired tetralogyofFallot (rTOF)and residual subpulmonary stenosiswithout ventricular tachycardia
(VT). Isthmus 3 bordered by the ventricular septal defect (VSD) patch and the PV consisting of ﬁbrous
tissue precluding its participation in VT. c CardiacMRI of a patientwith rTOF and severe PV regurgita-
tionwith RVOT dilatation andVT related to a slow-conducting anatomical isthmus 3. Intraoperative
cryoablation of isthmus 3 connecting the PV and the VSDpatch (d).PApulmonary artery, SP subpul-
monary stenosis, RVOT right ventricular outﬂow tract, LA left atrium, LV left ventricle, PV pulmonary
valve, TA tricuspid annulus,VP VSDpatch
incision or the anterior RVOT transan-
nular patch; isthmus 2 by the pulmonary
annulus and the RV incision or an RVOT
patch sparing the pulmonary valve annu-
lus; and isthmus 3 is located between the
pulmonary annulus and the VSD patch.
Finally, isthmus 4 is bordered by the VSD
patch and the tricuspid annulus in the
about20 %ofTOFpatientswithmuscular
VSDs. Themajority, however, have a per-
imembranous VSD, excluding isthmus 4.
Accordingly, in two postmortem series
of TOF, isthmus 3 and 1 were present in
almost all specimens, whereas isthmus 2
and 4 were less frequently observed [22,
26]. Of interest, isthmus 3 may also be
present in complex TGA associated with
VSDs (. Fig. 2e) and in patients with
isolated VSD. Importantly, not all AIs
are related to VT [11]. Macro-reentrant
VTs are facilitated by slow conduction
often observed in areas with intervening
ﬁbrosis. Progressive interstitial ﬁbrosis
may be due to longstanding cyanosis in
those who undergo repair at an older
age and/or due to pressure or volume
overload in those with residual or new
lesions, but may also be the consequence
of aging [3]. Of interest, remodeling over
time may also be dependent on the ini-
tial characteristics of the AI. In a post-
mortem series of rTOF patients who sur-
vived surgery, isthmus 3was signiﬁcantly
narrower and thinner with more inter-
stitial and replacement ﬁbrosis than isth-
mus 1, perhaps predisposing isthmus 3
to further arrhythmogenic remodeling
[22]. Indeed, in rTOF patients who un-
derwentVTablation, isthmus3wasmore
frequently related to VT than the other
AIs [11].
Thecoincidenceofunexcitableanatom-
ical boundaries and pathological remod-
eling over time may explain the high
incidence of late macro-reentrant VT in




Most data on risk stratiﬁcation are de-
rived from patients with rTOF. Retro-
spective, observational studieshave iden-
tiﬁed several factors associated with VA
and SCD (. Tab. 1). Currently, primary
prevention ICD implantation is consid-
ered reasonable in selected adults with
TOF and multiple risk factors for SCD,
such as left ventricular (LV) systolic or
diastolic dysfunction, nonsustained VT,
a QRS width of ≥180 ms, extensive RV
scarring, or inducible sustained VT at
electrophysiological study [1, 17].
Risk stratiﬁcation in patients after the
atrial switch operation for d-TGA is even
more challenging. Symptoms of arrhyth-
mias and heart failure and documented
atrialﬂutterorﬁbrillationhavebeeniden-
tiﬁed as predictors of SCD. In addition,
sustained VT and SCD are more likely
in patients with additional anatomical
lesions, impaired RV function, NYHA
class III or greater, and a QRS duration
of ≥140 ms [10]. Primary prevention
ICD implantation may therefore be rea-
sonable in patients with a systemic RV
ejection fraction of <35%, particularly
in the presence of additional risk factors
[1, 17]. However, most of the afore-
mentioned risk factors have only limited
predictive value for an individual patient
and may no longer apply to the majority
of contemporary patients with rCHD.
The currently applied arterial switch
operation for d-TGA disconnects the
aorta and pulmonary trunk from their
arterial roots and connects them to the
correct ventricle. The LV serves as sys-
temic ventricle that may prevent the
occurrence of late VA.
Repair of TOF has changed from
a late transventricular repair after pal-
liative shunt operation to a combined
transatrial–transpulmonary approach,
now usually performed early in life. The
latter approach may prevent severe RV
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hypertrophy, RV and LV dysfunction,
and increased intraventricular pressure
and ﬁbrosis, all factors associated with
late VA and SCD. In addition, AIs 1 and 2
may also be prevented by the modern
approach, whereas isthmus 3 and occa-
sionally isthmus 4 cannot be avoided. In
those patients, a positive programmed
electrical stimulation (PES), deﬁned as
inducibility of a sustained MVT, may
remain an important tool to prove the
presence of a substrate for reentrant VT.
Inducibility strongly depends on the ap-
plied induction protocol often requiring
three extra stimuli and occasionally iso-
proterenol [16]. Of interest, inducibility
of the clinical VT could be achieved in
all patients with rCHD referred for VT
ablation if stimulation was performed
from a site close to the infundibular
septum [11].
A wide QRS (≥180 ms) and an in-
crease in QRS duration have consistently
been reported as important risk factors
for bothMVTand SCD[6]. QRSprolon-
gation has been associated with RV di-
latation and arrhythmogenesis explained
by a mechanoelectrical interaction [7].
However, a prolongedQRS durationmay
be explained not only by global conduc-
tion delay in a dilated RV. It can also
be due to morphological and functional
changes restricted to the RVOT and may
reﬂect conduction delay within AIs [25].
This is further supported by the ﬁnding
that surgical pulmonary valve replace-
ment (PVR) has been associated with
a reduction in RV volume but not with
a consistent reduction in QRS duration
after surgery [2].
Inaddition, replacing thevalvedidnot
eliminate the risk forMVTs, despite post-
operative improvement in RV volumes
and function [9]. An empirical surgical
cryoablation lesion at the time of PVR,
connecting the boundaries of the AIs,
has shown promising results in treating
and preventing MVT and has been sug-
gested as alternative to mapping-guided
intraoperative ablation [23].
Treatment for VT
Patients with rCHD and VAmay be SCD
survivors or present with often highly
symptomatic, fastVTs (. Fig. 3). Accord-
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Abstract
Ventricular arrhythmias are an important
cause of late morbidity and sudden cardiac
death in the growing population of adults
with repaired congenital heart disease. Risk
stratiﬁcation remains challenging because
of the heterogeneity of the malformations
and the surgical approaches. Therapeutic
interventions depend on the type of ventric-
ular arrhythmia, which can be polymorphic
ventricular tachycardia (VT) or ventricular
ﬁbrillation in patients without ventricular
scars, but also potentially fatal monomorphic
reentrant VTs, typical for patients with
ventricular scars or obstacles. Advances in
surgical techniques have improved survival
and have important implications for the
arrhythmia substrates and prognosis. Over
the past few decades, progress has been
made to determine the anatomical basis
for monomorphic VT in patients with
ventricular surgical scars and patchmaterial.
These substrates can be currently identiﬁed
and targeted during sinus rhythm by
radiofrequency catheter or surgical ablation
without the need for VT induction. The review
provides an update on the evolving surgical
approaches, the changing VA substrates, and
the potential consequences for individualized
risk assessment and tailored treatment.
Keywords
Ventricular tachycardia · Repaired congenital
heart disease · Tetralogy of Fallot · Catheter
mapping · Radiofrequency catheter ablation
Kammertachykardie bei korrigierten angeborenen
Herzerkrankungen
Zusammenfassung
In der an Zahl zunehmenden Gruppe Erwach-
sener mit einer korrigierten angeborenen
Herzerkrankung sind Kammerrhythmus-
störungen eine wichtige Ursache für späte
Morbidität und plötzlichen Herztod. Eine
Risikostratiﬁzierung gestaltet sich i. Allg.
schwierig aufgrund der Heterogenität
der Fehlbildungen und der chirurgischen
Eingriﬀe. Therapeutische Interventionen
sind abhängig von der Art der Kammer-
rhythmusstörung. Polymorphe ventrikuläre
Tachykardien (VT) und Kammerﬂimmern
können bei Patienten ohne chirurgische
Narben oder eingebrachtes Fremdmaterial
im Ventrikel auftreten, während potenziell
letale monomorphe Reentrytachykardien
typisch für Patienten nach chirurgischen
Interventionen an den Hauptkammern
sind. Technische Weiterentwicklung
führte nicht nur zur Verbesserung der
Überlebenschance, sondern auch zu einem
wichtigen Einﬂuss auf die Entwicklung des
speziﬁschen arrhythmogenen Substrats und
der Prognose. In den letzten Jahrzehnten
wurden große Fortschritte darin erzielt, die
anatomischen Grundlagen für monomorphe
Reentrytachykardien bei Patienten mit
korrigierten angeborenen Herzerkrankungen
zu identiﬁzieren. Dieses Substrat für VT kann
während eines stabilen Sinusrhythmus rekon-
struiert und die identiﬁziertenGebietemittels
Radiofrequenzkatheterablationoder während
eines operativen Eingriﬀs behandelt werden,
ohne eine VT zu induzieren. Im vorliegenden
Übersichtsartikelwerden die Veränderungen
und Konsequenzen chirurgischer Interventio-
nen, die wichtigsten neuen Erkenntnisse über
Substrate von Kammertachykardien und die




Ventrikuläre Tachykardie · Korrigier-
te angeborene Herzerkrankungen ·
Fallot-Tetralogie · Katheter-Mapping ·
Radiofrequenzkatheterablation
ing to current guidelines, an ICD should
be implanted in SCD survivors after ex-
clusion of a reversible etiology. Of im-
portance, 70% of the patients with rTOF
who have received an ICD for primary
or secondary prevention required ICD
shocks to terminate the ﬁrst arrhythmia
[14]. Even if ATP was programmed and
delivered appropriately, it failed in 81%
of patients with rCHD [18]. Therefore,
additional therapeutic interventions are
needed.
There are no speciﬁc data available on
the eﬃcacy of antiarrhythmic drugs in
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Fig. 29 Postmortem spec-
imens of repaired tetralogy
of Fallot (rTOF; a–c), unre-
paired TOF (d), and unre-
paired dextro-transposi-
tionof thegreat arteries (e).




citable borders are (po-
tential) patches (ventric-
ular septal defect patch is
folded back in c), PV and
TA. Schematic of AIs 1–4
in rTOF (f). PV pulmonary
valve, TA tricuspid annulus,
RVOT right ventricular out-
ﬂow tract,VSD ventricular
septal defect
Fig. 39 a Clinical, fast ven-
tricular tachycardia (VT).
Please note QRpattern in
V1, consistentwith clock-
wise propagation through
anatomical isthmus (AI) 3
borderedby thepulmonary
valve (PV) and the ventric-
ular septal defect patch
(VP).bVoltagemapwith
awide AI I (normal volt-
age) bordered by a small
transannular patch (TP)
and tricuspid annulus (TA)
and a narrowAI 3 (width,
16.7mm). cActivationmap
during sinus rhythm. Isth-
mus 3was the only slow-
conducting AI (conduc-
tion velocity = 0.4m/s) and
related to VT, as demon-
strated by pace-mapping
(pace-match of VTwas ob-
tainedat site B; not shown).
d Connecting the PV and
VPwith a linear RF lesion
resulted in blocking of AI 3
preventing VT re-induction
andVT recurrence
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Tab. 1 Reported risk factors for VT and/or
SCD in rTOF
Older age at repair
Transannular patch
RV parameter (moderate to severe dysfunc-
tion, severe dilatation, LGE, akinetic region
length, mass/volume ratio ≥0.3 g/ml)
Moderate to severe PVR
LV parameter (moderate to severe dys-
function, longitudinal strain, end-diastolic
pressure)
History of atrial arrhythmias
(Pre)Syncope
QRS duration (≥180 ms), QRS duration in-
crease per year
Nonsustained VT
Inducible for MVT/PVT at PES
RV right ventricle, LGE late gadolinium
enhancement, PVR pulmonary valve re-
gurgitation, LV left ventricle, VT ventricular
tachycardia, MVTmonomorphic ventricular
tachycardia, PVT polymorphic ventricu-
lar tachycardia, PES programmed electrical
stimulation, rTOF repaired tetralogy of Fallot,
SCD sudden cardiac death
rCHD. In general, the available drugs to
prevent recurrence of reentrant VT in
structural heart disease have limited eﬃ-
cacy. Sotalol or Amiodarone may be ef-
fective in reducing appropriate ICD ther-
apy but their use is often hampered by
serious side eﬀects leading to drug dis-
continuation. The feasibility of radiofre-
quency catheter ablation (RFCA) in pa-
tients with rCHD was reported 20 years
ago, the majority performed in TOF pa-
tients, followed bypatientswithVSDclo-
sure andatrial switch for complexd-TGA
[8]. Initially only slow and hemodynam-
ically tolerated VT could be targeted,
approachable by conventional mapping
techniques, such as activation and en-
trainment mapping during ongoing VT.
Overthe lastdecade, progresshasbeen
made in identifying the anatomical sub-
strate for fast VTs, which is currently ap-
proachable by substrate-based ablation
techniques [11, 20, 26]. RFCA is per-
haps the most important treatment op-
tion, which should be considered as ad-
junct to ICD therapy. Although an ICD
is often indicated in patients with spon-
taneous sustained VT, catheter ablation
or surgery may even oﬀer a reasonable
alternative to ICD therapy in carefully
selected patients [11, 23].
Up to 97% of all spontaneous and
induced monomorphic VTs in the con-
temporary population of patients with
rCHD referred for RFCA or studied for
risk stratiﬁcation are macro-reentrant
VTs with a critical reentry circuit isth-
mus located within anatomically deﬁned
isthmuses [11].
These AIs can be reconstructed with
point-by-pointelectroanatomicalvoltage
mapping during stable sinus rhythm us-
ing three-dimensional electroanatomic
mapping systems (. Fig. 3). Peak-to-
peak bipolar electrogram amplitudes
can be displayed color-coded as a volt-
age map and projected on a three-
dimensional shell of the RV. In ad-
dition, local activation times derived
from bipolar and unipolar electrograms
can be displayed as an activation map.
Electrograms greater than 1.5 mV are
considered normal voltage. At sites with
amplitudes less than 0.5 mV, high-output
pacing (10 mA, 2 ms) can be performed
to identify unexcitable tissue. Noncap-
ture sites, consistent with patch material
or surgical scars, serve as boundaries of
AIs [11, 26].
The critical reentry circuit isthmus of
each induced VT can be occasionally de-
termined by activation and entrainment
mapping for toleratedVT.However, con-
sidering the often hemodynamically un-
stable VTs, pace-mapping within AIs is
often applied to determine whether the
critical isthmus is likely locatedwithin an
anatomically deﬁned isthmus. The VT-
related AI can be transected by connect-
ing the adjoining anatomic boundaries
by a linear RF lesion [26].
An alternative approach for mapping
of poorly tolerated VTs has applied non-
contact mapping [20]. The system, con-
sisting of a multielectrode balloon ar-
ray, allows for the simultaneous acquisi-
tion of virtual unipolar electrograms and
recording of the activation sequence re-
quiring only a single VT beat. The VT
circuit and the critical VT isthmus can
be displayed on the anatomic shell and
the corresponding AI can be targeted by
RFCA.
Demonstration of conduction block
after transection of an AI is an accepted
and clearly deﬁned procedural endpoint.
Accordingly, noninducibility of any VT
and transection of the critical AI was
deﬁned as complete procedural success
and achieved in 25 of 34 adults with VT
after CHD repair. None of these pa-
tients had recurrence of a monomorphic
VT during 46 ± 29 months of follow-
up [11]. These data strongly support the
concept that speciﬁc “arrhythmogenic”
AIs are the substrate for macro-reen-
trant VT in rCHD that can be eﬀectively
treated by catheter ablation. Conﬁrmed
conduction block of the arrhythmogenic
AI should be attempted and, if success-
ful, may be considered curative in pa-
tients with preserved cardiac function




The 12-lead morphology of the clinically
documented or induced VTmay already
provide an indication of the AI being
involved (. Fig. 3). However, speciﬁc
electroanatomical characteristics, in-
cluding isthmus width and conduction
velocity through an AI, may allow for
direct identiﬁcation of the “arrhythmo-
genic” AI that needs to be targeted by
ablation. This information is available af-
ter the three-dimensional reconstruction
of voltage and activation maps during
stable sinus rhythm. In a cohort of
74 TOF patients, only electroanatomical
narrow and slow-conducting AIs (cal-
culated conduction velocity <0.5 m/s)
were the substrate for all 37 documented
and induced MVTs in 24 patients with
preserved cardiac function (unpublished
data). The inability to transect an AI
may be due to the hypertrophied my-
ocardium preventing transmural lesions.
Perhaps more important, patch material
or a pulmonary homograft implanted
for late pulmonary valve regurgitation
may cover parts of the arrhythmogenic
isthmus 3. Occasionally, a left-sided ap-
proach from the aortic root orLVoutﬂow
tract canbe successful for transecting this
isthmus [12]. In patients who need to
undergo re-operation, preoperative PES
and electroanatomical mapping followed
by preventive intraoperative ablation of
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potentially arrhythmogenic AIs should
therefore be considered.
Conclusion
Risk stratiﬁcation and treatment of com-
plex VAs in patients with rCHD remain
challenging and require a multidisci-
plinary approach. Progress has been
made in understanding and delineating
the substrate for MVT. The strong link
between slow-conducting AIs and the
often poorly tolerated VTs allows for
RFCA without VT inducibility and (pre-
ventive) surgical ablation in those who
need surgical re-interventions. Substrate
identiﬁcationmayovercome theproblem
of lacking clinical arrhythmia predictors
and could facilitate personalized risk
stratiﬁcation and tailored treatment in
the contemporary population of patients
with rCHD.
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